Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SuperGen Nixes Phase III For Orathecin Combination Use In Pancreatic Cancer

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

SuperGen is pulling the plug on plans for a randomized Phase III trial of its Orathecin combination therapy in first-line pancreatic cancer after a Phase II study fell short of a pre-specified threshold for median survival

You may also be interested in...



MGI Submits Saforis NDA: Pipeline To Propel Sales To $1 Bil. By 2010 – Firm

MGI Pharma’s recently submitted oral mucositis therapy Saforis and newly approved myelodysplastic syndromes agent Dacogen top a "deep and maturing pipeline" projected to drive corporate sales to $1 bil. by 2010, according the company.

SuperGen Will Pursue Orathecin As Combo Therapy Following NDA Withdrawal

SuperGen may develop Orathecin as combo therapy following NDA withdrawal. Firm withdrew application in advance of anticipated negative action from FDA. SuperGen is moving ahead with a combination trial with gemcitabine

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel